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 CURRENTOPINION Are dietary fish oil supplements appropriate
for dyslipidemia management? A review of
the evidence
Samuel C.R. Sherratta, Michael Leroa,b, and R. Preston Masona,c
Purpose of review
The purpose of this review is to assess whether dietary fish oil supplements can be appropriate for patients
with elevated triglycerides and cardiovascular risk based on a comprehensive analysis of their composition,
and level of regulatory oversight.
Recent findings
Approximately 19 million people in the United States take fish oil supplements, many for the purpose of
treating or preventing heart disease. Unlike prescription products, fish oil supplements are classified as
food by the Food and Drug Administration (FDA) and are not required to undergo manufacturing oversight
or clinical testing. Analysis of widely used dietary fish oil supplements show that they may have lower
amounts of v-3 than advertised as well as significant levels of saturated fat and oxidized oils which
actually may contribute to dyslipidemia. Clinical outcome trials have failed to show a consistent
cardiovascular benefit with fish oil supplements and other low-dose mixed v-3 fatty acids.
Summary
In light of limited regulatory oversight and evidence of quality concerns, dietary fish oil supplements are not
an appropriate substitute for FDA approved prescription v-3 fatty acids for their indicated use in treatment
of elevated triglycerides or the prevention of cardiovascular events.
Keywords
fish oil, oxidized lipids, supplement
INTRODUCTION
The United States Department of Health and
Human Services on complementary and alternative
medicine use among adults and children states that
fish oil supplements are the most commonly used
supplements among adults in the United States [1].
Fish consumption is recommended in the 2015–
2020 Dietary Guidelines for Americans and by the
American Heart Association [2]. Although widely
available, fish oil supplements are not subject to
approval and oversight by the Food and Drug
Administration (FDA), as they are not over-the-
counter (OTC) drugs, so their content and chemical
integrity are not carefully regulated [3]. Addition-
ally, their efficacy is not assessed prior to marketing
as they are classified by the FDA as a food product
[3]. Yet millions of consumers, including patients
with dyslipidemia, take dietary fish oil supplements,
many in the hopes of preventing or treating heart
disease, despite the absence of supporting evidence
for their clinical efficacy.
DIETARY FISH OIL SUPPLEMENT
MANUFACTURING PROCESS, QUALITY,
CONTENT, AND EFFICACY
Eicosapentaenoic acid (EPA) and docosahexaenoic
acid (DHA), both v-3 polyunsaturated fatty acids
(O3FAs), are the valued components in fish oil
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supplements. However, these and other fatty acids
are particularly susceptible to oxidation because of
multiple and conjugated double bonds. There are
various contributors to fatty acid oxidation, includ-
ing thermal-oxidation, autooxidation, photo-oxida-
tion, metal-catalyzed oxidation, and ionically
catalyzed oxidation [4]. During the manufacturing
process of fish oil supplements, fatty acids may be
exposed to such oxidation pathways without careful
regulatory oversight. For example, to aid in the
coagulation of tissue protein and expression of
the oils, the harvested fish used for these supple-
ments are heated while exposed to atmospheric
oxygen. In addition, fish oil becomes oxidized
through exposure to metals and enzymes found
naturally in the fish [5–7]. Primary oxidation prod-
ucts of fatty acids include hydroperoxides, which
often degrade further into secondary oxidation
products such as aldehydes and ketones. These
chemical changes contribute to a loss of biological
integrity of fish oil supplements and produce the
easily identifiable rancid odor. During oxidation,
levels of EPA and DHA decline, whereas peroxide
levels increase [8], and the products of the oxidation
reactions may contribute to cardiovascular risk and
other chronic diseases.
Independent studies from various laboratories
have verified concerns about the integrity of fish oil
supplements as well as the actual levels of O3FA
compared with what is advertised. A study funded
by the US Department of Agriculture found that
only 10 out of 47 fish oil supplements had EPA
levels at or above the dose indicated on their labels.
Further, only twelve of these products reported
accurate amounts of DHA, whereas 74% contained
less than the stated label amounts of EPA or DHA [9].
In another study from New Zealand, 32 fish oil
supplements were analyzed for fatty acid content,
of which only 9% had O3FA levels that met or
exceeded stated label amounts [10]. Of the total
number of products tested, more than 80% were
found to have levels of lipid peroxides, a biomarker
of oxidation, which exceeded industry standards.
Further, only 8% of the supplements met interna-
tional standards for peroxide and total oxidation
levels [10].
In another study, the quality of leading fish oil
supplements (by sales) in the United States was
compared with a prescription O3FA product with
respect to EPA and DHA levels, the quantity and
oxidation status of other fatty acids [11]. In addition
to EPA and DHA, the supplements contained more
than 30 different fatty acid variants. This included
10–14 saturated fat species that constituted up to
36% of the total fatty acid content. In one of the
products, the amount of two saturated fats, palmitic
acid and myristic acid, was nearly equivalent to the
total EPA and DHA content (28 and 30%, respec-
tively). The supplements were also analyzed and
compared with a prescription v-3 formulation for
total oxidation (TOTOX), a composite of primary
oxidation products measured as peroxide value and
secondary oxidation products represented by anisi-
dine value. The supplements exceeded the interna-
tional threshold (as determined by the US Council
for Responsible Nutrition) for peroxide value and
TOTOX, and two of the three exceeded the thresh-
old for anisidine value. By comparison, the FDA-
approved O3FA prescription product did not have
detectable levels of oxidized lipids or saturated fats.
The fish oil supplement which contained a mixture
of oxidized and nonoxidized EPA and DHA failed to
inhibit lipoprotein oxidation compared with non-
oxidized O3FAs. The data summarizing these find-
ings can be found in Fig. 1a and b.
Similar findings with fish oil supplements and
oxidation were reported in another North American
study, which analyzed multiple lots of 16 fish oil
supplements with respect to EPA and DHA content
and oxidation levels [12]. Of the 16 products ana-
lyzed, only nine met their stated label claims for
total EPA and DHA. Three of the products that failed
to meet the stated EPA and DHA claims were man-
ufactured by GOED (Global Organization for EPA
and DHA) members. With regard to oxidation (mea-
sured as peroxide value), five of the products tested
exceeded the limit established in the GOED Volun-
tary Monograph and the European Pharmacopeia
Monograph. The two products that contained fatty
acids (either partially or completely) as ethyl esters
had the highest levels of oxidation with one having
more than five times the limit.
Elevated levels of oxidized fatty acids in fish oil
supplements may be expected to compromise any
biological benefits. Although the favorable lipid and
antiinflammatory effects of these products are often
KEY POINTS
 Fish oil supplements are classified by the FDA as food
and therefore do not require rigorous clinical testing or
oversight in manufacturing.
 Widely used fish oil supplements have been shown to
have variable levels of O3FAs while containing
oxidized lipids and saturated fats that can actually
contribute to dyslipidemia.
 Dietary fish oil supplements should not be considered
an effective alternative to carefully regulated
prescription v-3 products for patients at risk for
cardiovascular disease.
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cited as away to prevent cardiovascular disease, these
benefits may be partly or completely negated by the
lipid oxidation by-products prominently found in
fish oil supplements [13,14]. In a randomized con-
trolled trial involving healthy patients, administra-
tion of oxidized fish oils over seven weeks
contributed to dyslipidemia, including an elevation
in non-high density lipoprotein (HDL) cholesterol
levels, compared with patients administered a pri-
marily nonoxidized fish oil [15]. The lack of thera-
peutic efficacy with oxidized fish oil supplements
includes no improvement in lipid or inflammatory
parameter levels [16] as well as blood lipid levels [17].
Beyond lipid oxidation and saturated fats in
these products, there is evidence that fish oil proc-
essing technology may contribute contaminants
linked to increased risk of cancer and cardiovascular
disease. An analysis of oils obtained from marine
fish species indicated elevated levels of dioxin and
dioxin-like polychlorinated biphenyls (dl-PCBs)
higher than the maximum allowable limits for
human consumption [18]. Refinement of the oils
with activated carbon filters significantly reduced
the presence of these compounds, but not non-
dioxin-like PCBs because of the lack of affinity these
compounds for activated carbon. This indicates that
the activated carbon alone is not sufficient for
removing all harmful organic pollutants. Further-
more, results from this study showed that the refine-
ment process increased levels of 2 and 3-
monochloroproane-1,2-diols (MCPDs) in fish oils
with a higher prevalence of 3-MCPDs. This is signif-
icant because 3-MCPDs are classified as a possible
human carcinogen by the International Agency for
Research on Cancer. The above studies indicate that
the presence of oxidized oils and other organic
pollutants may be present in commercial fish oil
products and thus call into question their efficacy
and safety for human consumption.
BIOLOGICAL CONSEQUENCES OF
INGESTING OXIDIZED LIPIDS
The biological consequences of ingesting oxidized
lipids and the related oxidative products have been
characterized in cellular and animal studies but the
application to human pathology requires further
investigation. For example, 13-hydroperoxyoctade-
cadienoic acid (13-HPODE), a product of lipid oxida-
tion, has been shown to significantly alter cellular
functions. This includes an increase in vascular adhe-
sionmolecule expression in smoothmuscle cells [19],
causing human endothelial cells to express both
intracellular and surface adhesion molecules [20],
and activating kinase expression in aortic cells
[19,21]. 13-HPODE also induces inflammation by
causing elevated caspase-3 activity in enteric epithe-
lial cells and by activating MCP1 in human vascular
smooth muscle cells [22–24]. Lipid peroxidation,
once initiated, increases exponentially, which alters
membrane fluidity, cell signaling, and cell transport
[25]. Evidence also suggests that long-term lipid per-
oxidation may contribute to the development of
various diseases, including Alzheimer’s disease and
cancer [26,27]. Oxidized polyunsaturated fatty acids
(PUFAs) have also been associated with hemolytic
anemia, hepatomegaly, liver inflammation, and car-
diomyopathy [28].
FIGURE 1. Summary of fatty acid content in three leading (by sales) fish oil supplements in the United States (a) and summary
of oxidation (TOTOX) products in three leading (by sales) fish oil supplements from the United States (b). The international
threshold for TOTOX levels in supplements is 26. Results show as percentage change versus the threshold for TOTOX values in
three leading fish oil supplements following normalization to 1g total v-3 fatty acid. There was no evidence of significant
oxidation in the prescription product analyzed (data not shown). Data taken from [11].
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Oxidative modification of lipids has been linked
to an increase in inflammation through the nuclear
factor kappa-B (NF-kB) pathway [29] and insulin
resistance [30,31]. The degree of oxidative stress in
an organism can be quantified by measuring oxida-
tion product levels, antioxidant levels, and the
potency of antioxidant enzymes. Hydroperoxides
lead to increased levels of H2O2 and subsequent
catalase upregulation [32,33]. Multiple studies have
shown that oxidized oils and their related oxidation
products compromise cellular functions. One study
found that treating cells with lipid hydroperoxides
caused an eight-fold rise in cell apoptosis [34]. Addi-
tionally, rats fed oxidized oils had significantly
lower a-tocopherol and glutathione levels in eryth-
rocytes when compared with controls [35]. A similar
study found that plasma a-tocopherol levels were
reduced by 60% when pigs were fed a diet contain-
ing oxidized fats, thus compromising the endoge-
nous antioxidant system and increasing risk for
disease progression [36].
The period when oxidation of membranes and
lipoproteins occurs is referred to as the lag phase and
is an indicator of the antioxidant capacity of mem-
branes and lipoproteins. The longer the lag phase,
the greater the antioxidant capacity of the lipid
particles [37]. Feeding rats oxidized oils can shorten
low density lipoprotein (LDL) oxidation lag phase
by as much as 25% [38]. In a clinical study, patients
that consumed oxidized oil had a shortened plasma
LDL-cholesterol oxidation lag phase by approxi-
mately 25% [39]. LDL that is more prone to oxida-
tion has been linked to an increased risk for
atherosclerosis [40–42].
Elevated levels of lipid hydroperoxides and reac-
tive aldehydes predict cardiovascular events in
patients with coronary artery disease (CAD) even
after adjusting for traditional risk factors including
cholesterol levels, obesity, and blood pressure
[43,44]. These studies showed an increase in hospi-
talization for heart failure and revascularization for
patients with CAD and elevated circulating lipid
peroxides at baseline. In healthy patients fed oxi-
dized oil, chylomicrons were found to have signifi-
cantly higher levels of serum thiobarbituric acid-
reactive substances (TBARS) when compared with
controls [39].
Animal studies also provide supporting evidence
for biological consequences of oxidized fatty acid
consumption, including a 33% increase in plasma
cholesterol levels with mice fed a diet containing
oxidized O3FAs as compared with control [45].
Healthy rats fed oxidized oil rich in peroxides had
a five-fold increase in serum lipoprotein peroxide
levels, indicating that dietary peroxides are readily
incorporated into lipoproteins [46]. Animals fed a
diet containing oxidized oil also had aortic athero-
mas that were twice as large as the lesions found in
control animals [47], whereas TBARS increased by
80% when rats were fed highly oxidized oil [48]. A
separate study found that feeding mice a diet con-
taining oxidized fat increased plasma LDL-choles-
terol by 26% compared with control animals [49].
Finally, feeding rats oxidized oils resulted in
increased levels of oxidation products in lipopro-
teins and caused the levels of oxidation products in
the liver to double [50]. A similar study showed that
liver levels of the antioxidant a-tocopherol were
reduced by 50% in rats fed oxidized oils [51].
CLINICAL FINDINGS FROM FISH OIL
SUPPLEMENTS AND PRESCRIPTION
FORMULATIONS
Early epidemiological studies as well as outcome-
based randomized clinical trials have suggested that
consuming higher levels of the O3FAs may reduce
the risk of heart disease [52–55]. More recent and
comprehensive reviews of the clinical data with
O3FAs have cast doubt on this conclusion [56
&
],
including a recent review that examined the effec-
tiveness of 24 supplements and diets in cardiovas-
cular prevention [57
&
]. The authors evaluated nine
systematic reviews and four randomized controlled
trials, which encompassed 277 trials and 992129
participants. Findings indicated that few nutritional
supplements or dietary interventions offered any
protection against cardiovascular disease or death.
Supplementation with O3FA, in particular, yielded
‘low-certainty’ evidence that they were associated
with reduced risk for myocardial infarction and
coronary heart disease.
Large clinical outcome trials using a mixed and
low-dose (1 g/day) O3FA have failed to demonstrate
cardiovascular benefit. The ASCEND trial - A Study
of Cardiovascular Disease in Diabetes trial;
NCT00135226 reported the effect of 1 g/day of pre-
scription O3FA therapy in 15480 patients with dia-
betes but without evidence of atherosclerotic
cardiovascular disease [58
&
]. The results failed to
demonstrate a reduction of first serious vascular
events in the O3FA arm. This is consistent withmost
prior studies of O3FA mixtures at low doses. A
similar failure was reported in the VITAL study -
Vitamin D and Omega-3 Trial; NCT01169259
among more than 25000 patients with low cardio-
vascular (CV) risk using again a low-dose prescrip-
tion O3FA 1g/day [59]. In this primary prevention
trial, there was no statistically significant decrease in
the primary composite cardiovascular endpoint or
cancer-associated endpoints. Although there was a
reduction in certain secondary endpoints such as
Are dietary fish oil supplements appropriate for dyslipidemia management? Sherratt et al.
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MI, these are only hypothesis generating and require
an appropriately powered study to test. Thus, in
these two studies with over 40000 patients, there
was a consistent lack using a low-dose O3FAmixture
with respect to primary prevention.
In contrast to negative studies with fish oil
supplements or low-dose mixed O3FA prescription
products, there was a beneficial clinical outcome
with a higher dose EPA-only prescription formula-
tion. The Reduction of Cardiovascular Events with
Icosapent Ethyl - Intervention Trial (REDUCE-IT)
trial was a randomized, double-blinded, placebo-
controlled trial designed to examine the benefits
of icosapent ethyl, a prescription, highly purified
ethyl ester of EPA at 4 g/day [60
&&
]. The primary
objective of this study was to determine if highly
purified EPA treatment reduces ischemic events in
statin-treated patients with elevated and high base-
line fasting triglyceride (TG) levels (150–499mg/dl)
and cardiovascular risk for clinical events. The trial
enrolled 8179 men and women with established
atherosclerotic cardiovascular disease or with type
2 diabetes and one additional risk factor. The pri-
mary endpoint was a composite of time to first event
for cardiovascular death, nonfatal MI, nonfatal
stroke, coronary revascularization, or hospitaliza-
tion for unstable angina and reported a highly sta-
tistically significant (P<0.001) 25% relative risk
reduction. Reductions in key secondary endpoints
were also significant, including a 20% reduction in
CV death, 31% reduction in MI, and a 28% reduc-
tion in stroke. Another study called STRENGTH
FIGURE 2. Summary of risks associated with ingestion of oxidized oils, including oxidized oils sourced from fish.
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(Statin Residual Risk Reduction with Epanova in
High CV Risk Patients with Hypertriglyceridemia;
NCT02104817) evaluated if a 4 g/d mix of EPA and
DHA was beneficial in statin-treated patients with
elevated TGs. Recently, this trial was terminated due
to futility at the recommendation of the indepen-
dent data monitoring committee. Thus, the only
O3FA proven to be of CV benefit on top of statin
therapy in outcome trials remains prescription EPA.
CONCLUSION
Fish oil supplements are classified by the FDA as
food, and thus, their approval and ongoing produc-
tion does not require robust FDA review. Fish oil
supplements – unlike prescription and OTC medi-
cations – do not need to demonstrate effectiveness
in placebo-controlled clinical trials. Patients who
consume these products are often confused by state-
ments suggesting a benefit to cardiovascular health
despite affirmative clinical evidence. In fact, a com-
prehensive review of the basic and clinical evidence
shows that widely used fish oil supplements contain
lower amounts of O3FAs than specified on the label
as well as saturated fats and oxidized oils that may
actually contribute to dyslipidemia and increased
cardiovascular risk. Consumption of oxidized oils
has been linked to increases in non-HDL cholesterol
and vascular changes associated with atherosclero-
sis, including inflammation, LDL oxidation, and
endothelial dysfunction (Fig. 2). The results of a
recent study showed a significant cardiovascular
benefit with a highly purified and quality-controlled
prescription preparation of EPA (4 g/day). Thus, die-
tary fish oil supplements should not be considered
an effective substitute for appropriate dosage of
prescription O3FA products, which are supported
by strict testing and ongoing oversight by FDA
(Fig. 3).
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